Corynoline

Corynoline is an isoquinoline alkaloid that primarily functions as an acetylcholinesterase inhibitor, affecting neurotransmitter metabolism. This compound demonstrates potential sedative and hepatoprotective properties through modulation of cholinergic signaling pathways.

Origin & History

Corynoline is an isoquinoline alkaloid isolated from the Corydalis genus, particularly from plants like Corydalis bungeana and Corydalis incisa. It appears as a white to off-white crystalline powder and is extracted using standard alkaloid isolation techniques.

Historical & Cultural Context

There are no documented historical or traditional medicinal uses of corynoline. It is derived from Corydalis bungeana, a known Chinese herb, but its use is confined to modern phytochemical isolation.

Health Benefits

• May inhibit cell adhesion, although evidence is based on preclinical studies. • Potential sedative effects, demonstrated in non-human studies. • Possible liver protection benefits, noted in laboratory settings. • Inhibits acetylcholinesterase, shown in in-vitro studies. • Forms reactive metabolites that conjugate with glutathione, suggesting a detoxification role.

How It Works

Corynoline exerts its primary effects through acetylcholinesterase inhibition, preventing the breakdown of acetylcholine and enhancing cholinergic neurotransmission. The compound also interferes with cell adhesion mechanisms and forms reactive metabolites during hepatic processing. Its sedative properties likely involve GABAergic pathways, though specific receptor interactions require further investigation.

Scientific Research

There are no human clinical trials, randomized controlled trials (RCTs), or meta-analyses available for corynoline. All reported pharmacological activities are based on preclinical studies without specific PMIDs.

Clinical Summary

Current evidence for corynoline is limited to preclinical in-vitro and animal studies, with no human clinical trials available. Laboratory studies have demonstrated acetylcholinesterase inhibition activity, though specific IC50 values and dosage parameters have not been extensively characterized. Animal models suggest sedative effects and potential liver protection, but these findings have not been validated in human subjects. The formation of reactive metabolites raises questions about long-term safety that require clinical investigation.

Nutritional Profile

Corynoline is a pure isoquinoline alkaloid compound (molecular formula C21H21NO5, molecular weight 367.39 g/mol), not a whole food or nutritional ingredient, and therefore does not possess a conventional macronutrient or micronutrient profile. It contains no meaningful carbohydrates, proteins, fats, vitamins, or dietary minerals in any functional sense. As a bioactive compound, its relevant chemical characteristics include: a benzylisoquinoline alkaloid backbone with two methylenedioxy groups and one methoxy substituent, structurally classified within the protopine-type alkaloid family. It is isolated primarily from Corydalis bungeana and related Papaveraceae family plants, where it occurs at trace concentrations (typically <0.1% dry weight of plant material). Bioavailability data in humans is absent; preclinical data suggests moderate lipophilicity (estimated logP ~2.5–3.0), which supports membrane permeability but also indicates potential for metabolic activation by cytochrome P450 enzymes (particularly CYP3A4 and CYP2D6), generating reactive metabolites that are captured by glutathione conjugation, implying first-pass metabolism may limit systemic bioavailability. No fiber, protein, or mineral content is applicable. The compound's entire nutritional relevance is confined to its pharmacologically active alkaloid structure rather than any nutrient contribution.

Preparation & Dosage

No clinically studied dosage ranges are available as there are no human studies. Consult a healthcare provider before starting any new supplement.

Synergy & Pairings

Glutathione, Milk Thistle, Bacopa Monnieri, Ginkgo Biloba, Alpha-Lipoic Acid

Safety & Interactions

The formation of reactive metabolites during corynoline metabolism raises potential concerns about hepatotoxicity with chronic use. No established safety profile exists for human consumption, and potential interactions with acetylcholinesterase inhibitor medications could lead to excessive cholinergic effects. Individuals with liver dysfunction should exercise particular caution due to metabolic concerns. Pregnancy and lactation safety data are unavailable, making use inadvisable for these populations.